MET and cancer: Siemann et al. reported that most clinical trials testing c-MET inhibitors in cancer have yielded little benefit to patients and have not adequately tested the concept of c-MET pathway inhibition due to the lack of appropriate patient selection criteria (Hughes and Siemann, 2018).